Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Denosumab May Help Prevent Bone Loss Bortezomib for Initial Therapy in Multiple Myeloma Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/12/2008 First Published: 1/1/2001


1.		Phase III Randomized Chemoprevention Study of Selenium in Participants With Previously Resected Stage I Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				18 and over				NCI				ECOG-5597 CAN-NCIC-BR16, CALGB-79803, NCCTG-E5597, SWOG-E5597, NCI-P00-0176, NCT00008385, BR16

Last Modified: 7/28/2008 First Published: 2/21/2003


2.		Phase II Randomized Pilot Chemoprevention Study of Celecoxib in Former Heavy Smokers At High Risk of Primary or Second Primary Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				45 and over				NCI				UCLA-0108074 NCT00055978

Last Modified: 6/10/2008 First Published: 5/28/2004


3.		Phase II Randomized Chemoprevention Study of Iloprost in Patients at High Risk for Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				18 and over				NCI				UCHSC-01279 NCT00084409

Last Modified: 6/10/2008 First Published: 8/6/2006


4.		Phase II Randomized Study of Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				40 to 80				NCI				UARIZ-HSC-0353 U01-CA-101204, NCT00363805

Last Modified: 8/13/2008 First Published: 8/18/2006


5.		Phase II Randomized Chemoprevention Study of Sulindac in Current or Former Smokers With Bronchial Dysplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				40 to 79				NCI				MAYO-03-1-02 MAY03-1-02, NCT00368927

Last Modified: 6/10/2008 First Published: 10/6/2006


6.		Phase II Randomized Study of Enzastaurin Hydrochloride in Preventing Non-Small Cell Lung Cancer in Former Smokers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				45 and over				NCI, Pharmaceutical / Industry				MCC-14787 MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816


7.		A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				45 and over				Pharmaceutical / Industry				10723 H6Q-MC-S009, NCT00414960

Last Modified: 4/29/2008 First Published: 12/12/2007


8.		Phase II Randomized Study of Defined Green Tea Catechin Extract in Former or Current Heavy Smokers With Abnormal Sputum Score

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				45 to 74				NCI				BCCA-H03-61083 H03-61083, BCCA-R03-1083, NCT00573885

Last Modified: 4/24/2008 First Published: 2/7/2008


9.		Phase II Randomized Study of Polyphenon E, A Defined Green Tea Catechin Extract, in Current or Former Smokers With Bronchial Dysplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				45 to 74				NCI				BCCA-H07-02401 H07-02401, NCT00611650

Last Modified: 5/31/2008 First Published: 11/10/2005


10.		Chemoprevention Study of Broccoli Sprout Extract in Smokers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Prevention				Active				Over 18				NCI				JHOC-J0427 JHOC-04051801, NCT00255775

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute